Mast Therapeutics, Inc. (MSTX) to Present MST-188 Data at ASH
- S&P 500 dips off record high, Dow rises on bank earnings
- Coinbase (COIN) Soars 52% in Public Debut
- JPMorgan (JPM) Reports a Q1 Beat on Revenue and Profit Fueled by Release of $5.2 Billion Reserved for Bad Loans; Shares Slightly Down
- Bernie Madoff, disgraced Ponzi schemer, dies at 82
- Goldman Sachs (GS) Q1 EPS Nearly Doubles Wall Street's View as Investment Banking Excels Amid SPAC and IPO Frenzy
Mast Therapeutics, Inc. (NYSE: MSTX), a clinical-stage biopharmaceutical company, today announced that it will be presenting data from an ex vivostudy of MST-188 (vepoloxamer), its lead product candidate, at the 56th Annual Meeting of the American Society of Hematology (ASH) taking place December 6 – 9, 2014 in San Francisco, California. The abstract entitled "Pro-coagulant Actions of Circulating Microparticles in Sickle Cell Anemia and Sepsis Associated Coagulopathy and their Modulation by a Triblock Polymer MST-188," will be presented as part of the Oral and Poster Abstracts Program on Sunday December 7, 2014 in Session 321: Blood Coagulation and Fibrinolytic Factors: Poster II, from 6:00-8:00pm PST in the Moscone Center, West Building, Level 1. In addition, the abstract has also been published in the November 14, 2014 supplemental volume of the journal Blood.
In the ex vivo study, which was conducted at Loyola University Medical Center, the supplementation of MST-188 to blood samples collected from healthy normal individuals, sickle cell anemia (SCA) patients and sepsis associated coagulopathy (SAC) patients resulted in significant decrease in thrombin generation and marked decrease of functioning microparticles. The decrease in thrombin generation with MST-188 supplementation ranged from 24-55%. Thrombin is an enzyme that controls the conversion of fibrinogen to fibrin, which promotes blood clotting. Circulating microparticles (MPs) represent vesicles and cellular fragments generated in microvascular angiopathic conditions which facilitate pro-coagulant actions and contribute to thrombin generation and associated inflammatory processes. MST-188 is a triblock polymer with affinity to hydrophobic surfaces which are generated in microangiopathic conditions and may also interact with the phospholipid component of MPs. To test the hypothesis that MST-188 may decrease the pro-coagulant effects of MPs, a functional method to access MPs levels and a thrombin generation assay was used.
Martin Emanuele, Ph.D., Senior Vice President, Development, said: "These results suggest that MST-188 (vepoloxamer) antagonizes the procoagulant properties of microparticles formed in sepsis and during sickle cell crisis. This is important because dysfunctional coagulation is a key part of the pathology underlying 'sludged' blood flow (especially in the microcirculation) in both conditions."
- The abstract entitled "Pro-coagulant Actions of Circulating Microparticles in Sickle Cell Anemia and Sepsis Associated Coagulopathy and their Modulation by a Triblock Polymer MST-188" will be presented by Jaweed Fareed, Ph.D., Professor of Pathology and Pharmacology at Loyola University Stritch School of Medicine;
- The abstract is available on the Company's website athttp://www.masttherapeutics.com/technology/publications/.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LCI Industries (LCII) Announces Prelim. 1Q21 Sales Above Consensus
- Praxis Precision Medicines (PRAX) Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN8A-DEE
- Sinclair Broadcast Group (SBGI) Annonuces Laurie R. Beyer to Board
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!